BofA raised the firm’s price target on Emerson (EMR) to $155 from $130 and keeps a Buy rating on the shares. The firm’s summit with distributors provided no big surprises, with the firm telling investors in a research note that short-cycle data points are not “great,” but not worse, and in some areas sound solid. BofA argues that a discount is warranted given by higher financial leverage and merger integration risks.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR:
